

**Public Forum 2005 by NPO International TRI Network on December 15th Thursday, 2005**

Time Frame	Topic	Chairs/Speakers
12:00-13:00	Open the Door (Venue: Hamagin Hall "Via Mare", Minato-mirai, YOKOHAMA)	
Part I - Introducton		Toyama and Kato
13:00-13:05	Opening Remarks	Saito
13:05-13:20	Understanding the Heart and Coronary Disease	Kato
13:20-13:35	The Evolution of PCI: From Research to Clinical Practice	Saito
13:35-13:50	Global Patient Needs and New Treatment Evaluation	Krucoff
Break		
Part II - Protecting Patients in New Treatment Research		Alexander and Sase
14:00-14:05	Opening Remarks	Sase
14:05-14:20	New Treatment Study Design and Patient Safety: Japan Rules	Ikeda
14:20-14:35	New Treatment Study Design and Patient Safety: USA Rules	Carey
14:35-14:50	New Treatment Study Results and Patient Safety: Japan Rules	Tsukano
14:50-15:05	New Treatment Study Results and Patient Safety: USA Rules	Zuckerman
Break		
ART III: Going Together: View from the Patient and View of the Future		Krucoff and Saito
15:15-15:20	Opening Remarks	Saito
15:20-15:35	Improved Care in Hospitals. That Do Research	Alexander
15:35-15:45	My Experience as a New Treatment Patient	Patient (VTR)
15:45-16:00	Importance of Clinical Research (Review from Iressa)	Nakamura
16:00-16:15	Importance of Fair Reporting (View from the Journalists)	Maemura
16:15-16:30	Harmonization by Doing and the Future	Sase
1630-16:40	Closing Remarks by PMDA, MHLW, FDA, Krucoff, Sase, Maemura and Saito	
Break		
PART IV: Personal Health Consultation (Service for General Participants by NPO members)		
16:45-17:30	Personal Health Consultation by Members of NPO International TRI Network	

<b>Saito</b>	<b>ShonanKamakura General Hospital</b>	<b>Shigeru SAITO</b>
<b>Toyama</b>	<b>Kanagawa Caridiovacular and Respiratory Center</b>	<b>Shin-ichi TOYAMA</b>
<b>Kato</b>	<b>Yokohama Rosai Hospital</b>	<b>Ken-ichi KATO</b>
<b>Sase</b>	<b>Jyuntendo University Medical School</b>	<b>Kazuhiro SASE</b>
<b>Nakamura</b>	<b>Kanagawa Caridiovacular and Respiratory Center</b>	<b>Mari NAKAMURA</b>
<b>Tsukano</b>	<b>Ministry of Health, Labor and Welfare (MHLW)</b>	<b>Masaaki Tsukano</b>
<b>Ikeda</b>	<b>Pharmaceutical and Medical Devices Agency (PMDA)</b>	<b>Kouji IKEDA</b>
<b>Zuckerman</b>	<b>US Food and Drug Administration (FDA)</b>	<b>Bram D. Zuckerman</b>
<b>Carey</b>	<b>US Food and Drug Administration (FDA)</b>	<b>Carole CAREY</b>
<b>Maemura</b>	<b>Nihon Keizai Shimbun, Inc. (Nikkei)</b>	<b>Satoshi MAEMURA</b>
<b>Krucoff</b>	<b>Duke Clinical Research Institute (DCRI)</b>	<b>Mitchell KRUCOFF</b>
<b>Alexander</b>	<b>Duke Clinical Research Institute (DCRI)</b>	<b>John ALEXANDER</b>
<b>Patient</b>	<b>One or two patients, whom Saito is consulting</b>	